Complement Inhibition in IgAN: An Interview
IgA nephropathy (IgAN) is the most common immune-mediated glomerular disease worldwide. Advanced understanding of the role of complement in IgAN pathogenesis has motivated the development of complement inhibition as a therapeutic strategy. In a Mini-Review recently published in AJKD, authors Jia Wei Teh, Sinead Stoneman, and provide an overview of the role of complement in the pathogenesis and progression of IgAN and summarize current and emerging complement-targeted IgAN therapies.
The complement system in the pathophysiology of IgA nephropathy. Complement involvement in the “4-hit” pathogenic model for IgA nephropathy. The glomerulus shows mesangial deposition of galactose-deficient IgA1-containing immune complexes, mesangial cell proliferation, a membrane attack complex in the capillary wall, complement activation, and early crescent formation. Figure 1 from Teh et al © National Kidney Foundation.
AJKDBlog’s Interviews Editor, Timothy Yau (@Maximal_Change) recently sat down with Drs. Teh and
If the embedded player above doesn’t work, please click here to watch the video interview. Special thanks to Drs. Teh and for their time and insight!
To view this Mini-Review by Teh et al [FREE], please visit AJKD.org:
Title: Complement Inhibition in Immunoglobulin A Nephropathy: A Mini-Review
Authors: Jia Wei Teh, Sinead Stoneman, and Michelle M. O’Shaughnessy
DOI: 10.1053/j.ajkd.2025.07.023
Leave a Reply